Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Segment Reporting Other Item Amount

Segment Reporting Other Item Amount at other companies

CONMED logo
CONMEDCNMD
$6.23M+6.4%
Century Communities logo
Century CommunitiesCCS
$22.22M+279%
EyePoint, Inc. logo
EyePoint, Inc. EYPT
$4.06M+16.7%
Essential Utilities logo
Essential UtilitiesWTRG
-$75K+74.4%
Equitable Holdings logo
Equitable HoldingsEQH
$371M-5.1%
Proto Labs logo
Proto LabsPRLB
$128.08M+5.2%

Segments

By segment

See full
Reportable Segment$2K0.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×